The Latest Breaking News from Ignyte

A Modified Herpes Virus Injected into Tumors Wins FDA Approval for Advanced Melanoma

The FDA approved Tudriqev, an engineered herpes virus injected into melanoma tumors, for patients whose disease progressed on PD-1 immunotherapy.

Medical Daily · Aug 11

FDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejections

FDA granted accelerated approval to Tudriqev with nivolumab for advanced melanoma after two rejections. Who qualifies and what evidence is still owed.

Medical Daily · Aug 8

FDA Advisers Back a Melanoma Treatment for Patients Who Ran Out of Options, and a Decision Is Due Monday

FDA advisers voted 10-3 to back Replimune's RP1 for advanced melanoma after two rejections. The agency's decision is due August 2.

Medical Daily · Jul 31